Cite

    Levy, S. et al. (2022). First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial. Therapeutic advances in medical oncology. p. . [Online].